Hematological Malignancy Clinical Trial
Official title:
A Phase 1 Study of SG301 in Subjects With Hematological Malignancies
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
After a screening period of up to 28 days for each study phase, qualified patients will be enrolled to receive their assigned dose of SG301, administered weekly for the first 2 cycles and every 2 weeks thereafter, until disease progression or intolerable toxicity, starting of a new anticancer treatment, withdrawal of consent, lost to follow up, death, or end of the study, whichever occurs first. The study consists of a dose escalation phase (Phase 1a) and a dose expansion phase (Phase 1b) in subjects with relapsed or refractory multiple myeloma and other hematological malignancies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04932967 -
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
|
||
| Not yet recruiting |
NCT02900768 -
Effects of Exercise on Allogeneic Stem Cell Transplant
|
N/A | |
| Recruiting |
NCT04082910 -
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05510089 -
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
|
N/A | |
| Terminated |
NCT04093622 -
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
|
||
| Recruiting |
NCT06225856 -
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT06106360 -
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
|
||
| Recruiting |
NCT02828462 -
Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
|
||
| Completed |
NCT01714180 -
Effect of Body Mass on Acyclovir Pharmacokinetics
|
N/A | |
| Completed |
NCT03241550 -
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
|
Phase 1 | |
| Completed |
NCT02598752 -
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
|
||
| Completed |
NCT02880709 -
The Effect of Special Diets in Hematological Cancer Patients
|
Phase 4 | |
| Completed |
NCT00894049 -
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
|
Phase 2 | |
| Completed |
NCT04687982 -
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
|
N/A | |
| Completed |
NCT00897260 -
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
|
N/A | |
| Recruiting |
NCT03850366 -
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
|
Phase 2 | |
| Not yet recruiting |
NCT06066255 -
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
|
Phase 2 | |
| Enrolling by invitation |
NCT05364359 -
Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy
|
N/A | |
| Recruiting |
NCT04841447 -
Membrane Target Detection for Leukemia Treatment
|
||
| Not yet recruiting |
NCT06279585 -
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
|
N/A |